CCHT(SZ:000661) Jin Rong Jie·2026-02-25 16:13Core Viewpoint - Changchun High-tech experienced a significant stock price increase, with a daily rise of 9.98%, reaching a price of 97.26 yuan, and a total market capitalization of 39.668 billion yuan, driven by the approval of a clinical trial application for a new pediatric drug [1] Group 1: Company Developments - The company announced that its subsidiary, GenSci, received approval for a clinical trial application for GenSci141 ointment, aimed at treating various conditions leading to male developmental issues in children [1] - GenSci has a robust pipeline with 15 first-class new drug projects at different stages of development, indicating a strong focus on innovation in pediatric and oncology treatments [1] - The company secured a $120 million upfront payment and potential milestone payments of $1.365 billion through the technology licensing of the GenSci098 project, enhancing its financial position [1] Group 2: Market Reaction - The stock market saw a surge in trading volume and discussions surrounding the company's innovative drug development and international expansion, reflecting increased investor interest [1] - Positive sentiment among investors is driven by the belief that the company's research pipeline is well-stocked and that technology licensing will provide long-term cash flow support, potentially leading to a valuation recovery [1] - Conversely, some investors express concerns over the company's declining past performance, the lengthy and uncertain nature of drug development, and the ongoing challenges in its transformation process, which may affect future earnings [1]